30 30 Horizons in Healthcare Research

Friday 1st March 2019, University Program

1.00 – 1.30 Registration and light lunch

1.30 – 1.35 Welcome and opening Julie McCrossin/ A patient’s perspective Prof Tony Keech Dr Teresa Chairs: Prof Alicia Jenkins & Julie McCrossin Anderson AM

1.35 – 1.45 Cardio-metabolic: 30 years in 10 minutes Prof Philip Aylward Dr Teresa Anderson is the Chief Executive of Sydney Local Health District, one of the 1.45 - 1.55 Cancer trials: 30 years in 10 minutes Prof John Simes leading public health services in . She has more than 35 years of experience 1.55 – 2.05 Neonatal trials: 30 years in 10 minutes Prof William Tarnow-Mordi as a clinician and health service executive. She has a well-established reputation 2.05 – 2.15 Return on investment of clinical trials A/Prof Rachael Morton for implementing strategies to foster innovation and best practice, supporting Global reach of Australian trials Prof Anna Nowak 2.15 – 2.30 Speaker collaboration and building partnerships. 2.30 – 2.45 The digital future Prof Jonathan Morris Teresa is an internationally recognised Biographies Speech Pathologist and is passionate 2.45 – 3.00 Panel discussion Julie McCrossin about developing programs and services to support and improve the health and 3.00 – 3.30 Afternoon tea wellbeing of all people in the community. In 2018 she was appointed a Member of Chairs: Prof Lisa Askie & Julie McCrossin the Order of Australia (AM).

3.30 – 3.45 RCTs in a self-improving health care system Prof John Zalcberg Dr Anderson is a member of seven Medical Research, Health and PHN boards and is 3.45 – 4.00 The future of clinical trial funding Prof Anne Kelso an active member of the Sydney Health Partners Governing Council and Executive 4.00 – 4.20 Data sharing in clinical trials Dr Jeff Drazen, MD Management Group, one of the first four centres in Australia designated by the 4.20 – 4.35 Panel discussion Julie McCrossin NHMRC as an Advanced Health Research Translation Centre. Chairs: Dr Teresa Anderson & Julie McCrossin

4.35 – 4.45 Prioritising research - A consumer’s perspective Melinda Cruz

4.45 – 5.00 Molecular & genomic driven trials – Precision medicine A/Prof Mustafa Khasraw

5.00 – 5.15 Attracting industry trials to Australia Dr Glenn Begley

5.15 – 5.30 Panel discussion Julie McCrossin

5.30 Wrap up and close Prof Tony Keech

5.30 – 7.30 Cocktail Reception, The Refectory Room, Holme Building Professor Professor Dr C. Glenn Melinda Lisa Askie Philip Aylward Begley Cruz

Professor Askie leads a team at the CTC, Professor Aylward is Professor of Medicine Dr C. Glenn Begley is the inaugural CEO Melinda Cruz is the mother of three babies , which manages the at Flinders University and the Director of of BioCurate, a joint initiative of Monash born prematurely and is the award-winning Australian New Zealand Clinical Trials Strategic Relationships within the Southern and Melbourne Universities, created to Founder of Miracle Babies Foundation, Registry, undertakes Health Technology Adelaide Local Health Network. He is a provide commercial focus in the early Australia’s largest and leading neonatal Assessments for the Australian Federal Member of the Innovation Centre within phases of drug development. consumer group. Melinda was appointed as Government, hosts two Cochrane SAHMRI Heart Health and leads the an Honorary Research Associate at the CTC, Collaboration entities (Breast Cancer development of Education Programmes. Glenn served as Chief Scientific Officer at and was the first parent to be an Associate Review Group, Prospective Meta-analysis Akriveia Therapeutics, California (2016– Investigator on a CTC neonatal trial, LIFT. Methods Group) and has an extensive Philip is a Cardiologist with over two 2017) and TetraLogic Pharmaceuticals, test evaluation research program. decades of involvement in clinical trials. Pennsylvania (2012–2016). From Melinda is a trusted consumer expert He has been a National Co-ordinator and 2002–2012, he was Vice-President and to medical professionals seeking to Lisa’s clinical background is in perinatal member of a number of international Global Head of Haematology/Oncology improve treatments and understanding medicine and she has worked in steering and executive committees in Research at Amgen, responsible for of premature and sick babies and the healthcare systems in Asia, Australia, cardiology, particularly in acute coronary building, directing and integrating Amgen’s impact a birth has on the family unit. In UK and USA. She has Masters and syndromes, lipid management, atrial five research sites. 2014, Melinda joined the PSANZ Consumer Doctoral qualifications in epidemiology fibrillation and heart failure. Advisory Panel and accepted a position from Sydney Medical School, is a Senior Before Amgen, Glenn had over 20 years on the PSANZ Clinical Trials executive Principal Research Fellow at the University Philip was Co-chair and author of the initial of clinical experience in medical oncology committee. In 2016, she was asked to of Sydney and has held an NHMRC Australian Guidelines for the Management and haematology. His personal research join the NHMRC Clinical Trials Ready Postgraduate Scholarship, a Sidney of Acute Coronary Syndromes 2006 and focused on regulation of haematopoietic Development Committee and contributed Sax Postdoctoral Fellowship, a Career was a Member of the 2017 Acute Coronary cells and translational clinical trials. to the dissemination of the results of Development Fellowship and currently, Syndrome Guidelines Writing Committee of His early studies first described human BOOST II and APTS trials. In 2015, she a Translating Research Into Practice the National Heart Foundation and Cardiac G-CSF, and in later clinical studies, first joined the Australian Red Cross Blood (TRIP) Fellowship. Society of Australia & New Zealand. demonstrated that G-CSF-mobilised blood Service Milk Bank Advisory Committee. stem cells hastened haematopoietic recovery. This finding revolutionised Under Melinda’s leadership, Miracle the clinical approach to bone marrow Babies Foundation has established a major transplantation. impact and reach, with almost 60,000 likes on Facebook and an active and engaged Glenn’s honours include being elected as audience on Twitter, Instagram and the first Foreign Fellow to the American LinkedIn. Melinda was recently invited to Society of Clinical Investigation in 2000, to become a regular contributor to THRIVE the Association of American Physicians in Global, an international portal for health 2008, to the Research ‘Hall of Fame’ at his and wellbeing, in which she has published alma mater, the Royal Melbourne Hospital, five articles to date. in 2014, and to the Australian Academy of Health and Medical Sciences in 2016. She is currently working on publishing her first book. Dr Jeff Professor Professor Professor Drazen Alicia Jenkins Tony Keech Anne Kelso

Dr Jeff Drazen joined the New England Alicia Jenkins is a Professor of Diabetes Professor Tony Keech is Senior Principal Professor Anne Kelso AO is the Chief Journal of Medicine (NEJM) as Editor- and Vascular Medicine at the CTC. She Research Fellow and Deputy Director of the Executive Officer of the NHMRC. Following in-Chief in July of 2000. In 2012, he was has collaborated with the CTC since 2000 CTC. He co-leads the research team at the her PhD at the University of Melbourne, appointed Editor-in-Chief of NEJM Group, and she and her team moved to the CTC CTC and for the last ten years has chaired Anne undertook research in the field of which also publishes NEJM Journal Watch, in 2012 / 13. She trained at the University the CTC’s Research Committee. immunology, first in Switzerland and then NEJM Knowledge+, NEJM Catalyst, NEJM of Melbourne (Australia), in Ireland, the at the Walter and Eliza Hall Institute of Resident 360, and NEJM Yi Xue Qian Yan. UK, and the US. She is an endocrinologist Tony is Professor of Medicine, Cardiology Medical Research in Melbourne and the with clinical and research interests in and Epidemiology at the University of Queensland Institute of Medical Research A specialist in pulmonology, Jeff maintains diabetes and its complications, including Sydney, an internationally renowned in Brisbane. an active research program. He has the use of technology in diabetes care, researcher in the field of cardiovascular published more than 300 articles on topics as well as insulin pumps, glucose sensors clinical trials, and Chair and Principal From 2000 until 2006, Anne was also such as lung physiology and the mechanisms and telehealth. With over 25 years of Investigator of the FIELD diabetes study. Director/CEO of the Cooperative Research involved in asthma. Throughout his research experience Alicia leads clinical His research has influenced health Centre for Vaccine Technology. She then distinguished career, he has served many and basic science research exploring outcomes, particularly in treatments of returned to Melbourne as Director of the academic and hospital appointments and diabetes and its complications, clinical, acute myocardial infarction, cardiovascular WHO Collaborating Centre for Reference received numerous honours. biochemical and molecular biomarkers, disease prevention of chronic heart and Research on Influenza from 2007 and trials, including the FIELD, T4DM, disease, and diabetes and its vascular until she took up her role with NHMRC Jeff is the Distinguished Parker B. Francis DCCT/EDIC, REMOVAL, FAME-1 trials and complications. He is recognised in April 2015. Professor of Medicine at Harvard Medical insulin pump studies. Alicia has over 350 internationally for collaborative research School, Professor of Physiology at the publications and mentors a wide range of into coronary risk factors, treatments for Anne is a current member of several Harvard School of Public Health, and a clinician researchers. She holds a NHMRC acute coronary syndromes, prediction government and international committees, senior physician at Brigham and Women’s Practitioner Fellowship, she has served on of vascular disease, and treatment and including the Australian Medical Research Hospital. In 2003, he was elected as a the Australian Diabetes Society Council, diabetes complication prevention. Advisory Board (advising the Minister member of both the Institute of Medicine is on the IDF Western Pacific Region for Health on the strategy and priorities for and the Royal Society of Medicine. Jeff has Executive Council and is President of Tony is a founding member of the Board of the Medical Research Future Fund), the served on numerous committees for the the Insulin for Life (global and Australia) Directors, Australian Clinical Trials Alliance Board of the Global Alliance for Chronic National Institutes of Health. diabetes charity. She and her team have (ACTA), formed in 2012 to promote Diseases and the Human Frontier Science extensive national and international effective and evidence-based healthcare Program Organization. Jeff earned his bachelor’s degree and collaborations. in Australia through investigator- graduated summa cum laude from initiated clinical trials. He is a consultant Anne was elected a fellow of the Australian Tufts University. He received his medical cardiologist at Royal Prince Alfred Hospital Academy of Science and the Australian degree from Harvard Medical School and and continues to teach students and Academy of Health and Medical Sciences completed his internship and residency at postgraduates in medicine, public health in 2018. Peter Bent Brigham Hospital in Boston. Jeff and epidemiology. was a clinical and a research fellow at both Harvard Medical School and the Harvard School of Public Health. Associate Associate Professor Julie Professor Professor Mustafa McCrossin AM Jonathan Rachael Khasraw Morris Morton

Associate Professor Mustafa Khasraw is a Julie McCrossin gets people talking. Professor Jonathan Morris is a graduate of Associate Professor Rachael Morton is Clinical Lead at the CTC with a leading role in After 20 years as a broadcaster with ABC the University of Edinburgh and completed Director of Health Economics at the CTC several clinical and translational programs. , ABC TV and Network his Obstetric and Maternal Fetal Medicine and an NHMRC TRIP Fellow. She has a He is also a practising medical oncologist at Ten, she is now a freelance journalist and sub specialty training in Sydney. He MScMed (Clin Epi)(Hons) and a PhD in Royal North Shore Hospital in Sydney. broadcaster. Julie writes for the NSW Law completed his PhD in Oxford and returned Health Economics from the University of Society Journal and LOTL Magazine and to Sydney in 1998 to the Royal North Shore Sydney. She spent two years working at Mustafa has worked in several countries facilitates conferences and seminars. Julie Hospital. Since then he has built a perinatal the Health Economics Research Centre, and received his MD from the University of has qualifications in the arts, education research group that extends from basic University of Oxford as part of her NHMRC Groningen in the Netherlands. He worked and law. After treatment for stage 4 throat science to population health. His major Sidney Sax Postdoctoral Fellowship. as an oncology fellow at Addenbrooke’s cancer in 2013, Julie is now an Ambassador research interests are the prediction, Hospital in Cambridge from 2005 to 2007, for Beyond Five, Targeting Cancer and prevention and management of pregnancy Rachael specialises in trial-based and and then began training as a medical TROG Cancer Research. Julie hosts the complications, which have led to a number modelled economic evaluation, and oncologist at Royal North Shore Hospital podcast series, The Thing About Cancer for of large clinical trials that have informed elicitation of patient preferences using in Sydney. In 2011, he completed a Cancer Council NSW. In 2019 Julie received practice in Australia and overseas. discrete choice experiments. Her research subsequent fellowship at Memorial Sloan- an AM for service to the community, incorporates patient-centred and economic Kettering Cancer Center in New York before particularly advocacy for LGBTI people and outcomes into clinical trials of diagnostic returning to Australia. the media. www.juliemccrossin.com tests, new treatments and models of care to facilitate policy decision-making on the Mustafa has worked at the CTC since 2012. basis of cost-effectiveness. He leads an extensive clinical trials team with significant laboratory collaborations Rachael is co-chair of the ACTA Research focusing on targeted therapies and Prioritisation working group, and President immuno-oncology in glioblastoma and of the Health Services Research Association other underserved cancers. He is lead of Australia and New Zealand (HSRAANZ). Principal Investigator on Phase I, II and She is a member of the Science in Australia III clinical trials for a number of ongoing Gender Equity (SAGE) team at the academic and pharmaceutical multi-centre University of Sydney, and Chair of its Data clinical studies with a special interest in Working Group. innovative trial design. Mustafa holds a Medical Research Future Fund Next Rachael coordinates short courses in Generation Clinical Trials Fellowship. health economics for government and industry and currently supervises five PhD candidates. She has published 120 articles in applied health economics and health services research. Professor Professor Professor William Professor Anna Nowak John Simes Tarnow-Mordi John Zalcberg

Professor Anna Nowak is a Medical Professor John Simes is Senior Principal Professor William Tarnow-Mordi is Director Professor John Zalcberg was the Director, Oncologist at Sir Charles Gairdner Hospital Research Fellow, Founder and Director of of Neonatal and Perinatal Trials at the CTC Division of Cancer Medicine, at the Peter (SCGH) and Professor within the School of the CTC. and Foundation Director of the WINNER MacCallum Cancer Centre in Melbourne, Medicine, University of Western Australia, Centre for Newborn Research at the Australia for 17 years prior to recently taking up with longstanding research and clinical He is a leading international researcher University of Sydney. the position of Head, Cancer Research Program interests in malignant mesothelioma and in clinical trials, particularly in cancer, in the School of Public Health and Preventive neuro-oncology. cardiovascular disease, diabetes and William completed his medical training Medicine within the Faculty of Medicine, neonatal medicine. He has contributed at the University of Cambridge, UK, Nursing and Health Sciences at Monash Anna is the current Chair of COGNO to over 300 peer-reviewed articles, with followed by specialist training in Paediatrics University. After earning a Bachelor of Medicine (CoOperative Group for Neuro-Oncology) many having a significant impact on current and Neonatal Medicine. He migrated and Bachelor of Surgery from the University of and the Director of the National Research knowledge and clinical practice. to Australia in 1999 to commence an Melbourne and a PhD in cancer immunology, Centre for Asbestos Related Diseases appointment as inaugural Professor of John served as Director of Medical Oncology (NCARD), an NHMRC Centre for Research John was the Founding Director of Neonatal Medicine, University of Sydney at the Heidelberg Repatriation Hospital and as Excellence. Sydney Catalyst Translational Cancer and as Director of Neonatology, Westmead Director of Cancer Services at the Austin and Research Centre, a virtual centre of cancer Hospital, where he led NSW’s busiest Repatriation Medical Centre. After a laboratory-based PhD in tumour researchers in central Sydney and regional neonatal department until 2010. immunology Anna was the inaugural NSW. He is a founding member of the Board John has over 250 articles published in peer- postdoctoral clinical trials fellow at the CTC. of Directors of the ACTA, formed in 2012 Trials in extremely premature babies are reviewed journals. A founder of the Lorne Cancer She has been Principal Investigator for a to promote effective and evidence-based challenging, and William and his team work Conference and the Australasian Gastrointestinal number of local and national clinical trials, healthcare in Australia through investigator- to form global partnerships to find cost- Trials Group (AGITG), he is immediate past including most recently the ALTG DREAM initiated clinical triaIs. effective treatments that will reduce infant Chair of the Board of AGITG after serving in study, and is an active member of COGNO mortality and illness. The CTC’s Neonatal this role for over 15 years and a past Board and ALTG trial management committees. John is a practising medical oncologist Research program focuses on areas of Member of Cancer Trials Australia. John is the in neuro-oncology at Royal Prince Alfred need, such as neonatal infection, oxygen current Co-Chair of the Cancer Drugs Alliance Anna also has interests in quality of life, Hospital and the Chris O’Brien Lifehouse, therapy and simple cost-effective measures and Chair of ACTA. He also serves on the Board imaging, staging, and tumour measurement, and is Professor of Clinical Epidemiology at to reduce health problems and improve of the Australian Red Cross Blood Service. and maintains a translational research Sydney Medical School, University of Sydney. outcomes for high-risk newborn infants. laboratory. John has received a Medal of the Order of His research has been recognised in a number William’s work has helped to improve Australia Award (OAM), the 2011 Cancer of awards including the NSW Premier’s Award survival rates in very preterm infants, Achievement Award from the Medical Oncology for Outstanding Cancer Research (2016), the influence clinical practice and achieve major Group of Australia and the 2015 Tom Reeve Alan Coates Award for Excellence in Clinical health care cost savings worldwide by Award for outstanding contribution to cancer Trials Research (2016), the Harvard Alum identifying ineffective treatments. He serves care from the Clinical Oncological Society of Award (Biostatistics) (2009), the MOGA on the Steering Group of NSW Health’s Australia (COSA). Cancer Achievement Award (2010) and the Better Treatment for Kids Network and is co- Vice-Chancellor’s Award for Outstanding chair of the Perinatal Society of Australia and In 2014 the AGITG announced the annual ‘John Research (2017, University of Sydney). He New Zealand Clinical Trials Working Group. Zalcberg OAM Award for Excellence in AGITG was named on the Clarivate Analytics World’s Research’ in his honour. Highly Cited Researchers List for 2018. Celebrating

30years